Kenneth J Kopecky
Overview
Explore the profile of Kenneth J Kopecky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
3087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pogosova-Agadjanyan E, Moseley A, Othus M, Appelbaum F, Chauncey T, Chen I, et al.
Biomark Res
. 2020 Aug;
8:29.
PMID: 32817791
Background: The recently updated European LeukemiaNet risk stratification guidelines combine cytogenetic abnormalities and genetic mutations to provide the means to triage patients with acute myeloid leukemia for optimal therapies. Despite...
2.
Rivkind N, Stepanenko V, Belukha I, Guenthoer J, Kopecky K, Kulikov S, et al.
Int J Epidemiol
. 2019 Oct;
49(2):448-456.
PMID: 31628796
Background: Ionizing radiation is a known cause of female breast cancer, but there have been few studies of the risk after prolonged radiation exposure at low dose rates. Methods: This...
3.
Wang C, Cullings H, Song X, Kopecky K
J R Stat Soc Series B Stat Methodol
. 2018 Jan;
79(5):1583-1599.
PMID: 29354018
Observational epidemiological studies often confront the problem of estimating exposure-disease relationships when the exposure is not measured exactly. In the paper, we investigate exposure measurement error in excess relative risk...
4.
Pogosova-Agadjanyan E, Moseley A, Othus M, Appelbaum F, Chauncey T, Chen I, et al.
Biopreserv Biobank
. 2017 Nov;
16(1):42-52.
PMID: 29172682
Introduction: Current prognostic models for acute myeloid leukemia (AML) are inconsistent at predicting clinical outcomes for individual patients. Variability in the quality of specimens utilized for biomarker discovery and validation...
5.
Cesano A, Willman C, Kopecky K, Gayko U, Putta S, Louie B, et al.
PLoS One
. 2015 Apr;
10(4):e0118485.
PMID: 25884949
Single-cell network profiling (SCNP) data generated from multi-parametric flow cytometry analysis of bone marrow (BM) and peripheral blood (PB) samples collected from patients >55 years old with non-M3 AML were...
6.
Stram D, Preston D, Sokolnikov M, Napier B, Kopecky K, Boice J, et al.
PLoS One
. 2015 Mar;
10(3):e0119418.
PMID: 25799311
Radiation dose reconstruction systems for large-scale epidemiological studies are sophisticated both in providing estimates of dose and in representing dosimetry uncertainty. For example, a computer program was used by the...
7.
Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum F, Evans A, et al.
J Clin Oncol
. 2015 Feb;
33(10):1157-64.
PMID: 25713434
Purpose: Younger patients with acute myeloid leukemia (AML) harboring NPM1 mutations without FLT3-internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD-negative genotype) are classified as better risk; however, it remains uncertain whether this favorable...
8.
Othus M, Appelbaum F, Petersdorf S, Kopecky K, Slovak M, Nevill T, et al.
Biol Blood Marrow Transplant
. 2014 Dec;
21(3):559-64.
PMID: 25536215
The aim of this study was to describe the fate of patients with newly diagnosed acute myeloid leukemia (AML) who did not achieve an initial remission while being treated on...
9.
Coutre S, Othus M, Powell B, Willman C, Stock W, Paietta E, et al.
Br J Haematol
. 2014 Feb;
165(4):497-503.
PMID: 24528179
Aa total of 105 patients (age ≥18 years) with newly diagnosed low or intermediate risk acute promyelocytic leukaemia (APL) were treated with a standard induction and consolidation regimen including arsenic...
10.
Edlefsen K, Martinez-Maza O, Madeleine M, Magpantay L, Mirick D, Kopecky K, et al.
Int J Cancer
. 2014 Feb;
135(4):913-22.
PMID: 24488825
Specific associations for lymphoma in the general population suggest that chronic immune dysfunction/dysregulation may be associated with the development of B-cell non-Hodgkin lymphoma (NHL). Furthermore, polymorphisms in several cytokine genes...